1315 Capital (Philadelphia, PA)
Michael joined 1315 Capital in 2014, after spending his entire career as a health care investor and operator, including experience with more than 20 growth equity investments. Most recently Michael spent four years as Managing Director at Palm Ventures, a private-equity focused family office. At Palm, he led all healthcare investing, including the purchase of Nutrition 21 Inc., forming the basis for JDS Therapeutics. In addition, Michael led investments in Enigma Diagnostics and Axcentria Pharmaceuticals.
Before Palm Ventures, Michael spent eight years as an investor, including before and after business school at Galen Partners, a healthcare growth equity investment firm, and three years on the operating side as a director of financial planning and business development at Novoste Corporation. Michael started his career as a healthcare investment banking analyst at Dillon, Read & Co.
Michael received a BSc in Economics from Cornell University and an MBA in Healthcare Management from The Wharton School.